← Back to headlines
Gossamer Bio Targets 2026 NDA Filing for Seralutinib
Gossamer Bio aims to file a New Drug Application (NDA) for its drug seralutinib by September 2026, with a potential approval anticipated in the third quarter of 2027.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
